Sanofi (SNY) stock
Close on Nov 18, 2026Market cap $114.92BP/E 13.4Yield –
Earnings
Sanofi's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Sanofi's earnings releases, newest first
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Sanofi's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| expected one-off COVID vaccine revenues | Q4 FY2023 | 400 | – | New | Oct 27, 2023 |
| currency impact on 2023 business EPSnon-GAAP | FY2023 | -7% – -6% | – | New | Oct 27, 2023 |
| effective tax ratenon-GAAP | FY2023 | 19% | – | New | Oct 27, 2023 |
Guidance history
Every forecast Sanofi put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 27, 2023 | currency impact on 2023 business EPS | FY2023 | -7% – -6% | New |
| Oct 27, 2023 | effective tax rate | FY2023 | 19% | New |
| Oct 27, 2023 | expected one-off COVID vaccine revenues | Q4 FY2023 | 400 | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Adjusted figures
Non-GAAP numbers Sanofi reports itself, taken from its earnings releases
| Measure | Q2 FY2023 |
|---|---|
| Business operating income | €4.03B |
| Business net income | €3.20B |
| Business EPS | 2.55 EUR |
| Free cash flow | €1.85B |
Read from the company's own earnings releases; hover a figure for the sentence it came from. Companies choose what to leave out of an adjusted number and there is no standard for it, so these are not comparable between companies the way the audited statements are. Margins here are computed from the adjusted revenue of the same period.
Press releases
Releases Sanofi filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?